caa a22 4500 469026480 CHVBK 20180323132731.0 cr unu---uuuuu 170328e19920801xx s 000 0 eng 10.1007/BF01962544 doi (NATIONALLICENCE)springer-10.1007/BF01962544 Vermeij Pieter Department of Clinical Pharmacy and Toxicology, University Hospital Leiden, P.O. Box 9600, 2300, RC Leiden, the Netherlands aut Cardiovascular drugs [Elektronische Daten] [Pieter Vermeij] Since the category of cardiovascular drugs comprises a considerable number of pharmacotherapeutic groups, an overview of future developments must necessarily be limited to those areas in which innovations are most likely to occur. Further extension of our knowledge of thrombolytic therapy may eventually lead to new choices of primary drugs. In the area of antiarrhythmic therapy, the clinical use of a number of drugs has been hampered by the pro-arrhythmogenic actions of these agents. The development of new class III anti-arrhythmics will continue, probably giving rise to new therapeutic options. In the vascular area a new group of drugs, the renin inhibitors, is likely to emerge for the treatment of hypertension. Moreover, exciting discoveries in vascular pharmacology should eventually translate into new pharmacotherapeutic approaches. Finally, the large-scale availability of blood fractions (coagulation factors) prepared by recombinant technology may help solve current shortages of products derived from donated blood. Royal Dutch Association for Advancement of Pharmacy, 1992 Antiarrhythmic drugs nationallicence Cardiovascular drug innovation nationallicence Thrombolytics nationallicence Renin inhibitors nationallicence Recombinant blood coagulation factors nationallicence Pharmaceutisch Weekblad Kluwer Academic Publishers 14/4(1992-08-01), 224-228 0031-6911 14:4<224 1992 14 11096 https://doi.org/10.1007/BF01962544 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF01962544 text/html Onlinezugriff via DOI NATIONALLICENCE 100 1- Vermeij Pieter Department of Clinical Pharmacy and Toxicology, University Hospital Leiden, P.O. Box 9600, 2300, RC Leiden, the Netherlands aut NATIONALLICENCE 773 0- Pharmaceutisch Weekblad Kluwer Academic Publishers 14/4(1992-08-01), 224-228 0031-6911 14:4<224 1992 14 11096 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer